Positive data will underpin GSK plans to file its GLP-1 RA albiglutide in early 2013
This article was originally published in Scrip
Competition in the glucagon-like peptide 1 receptor agonists (GLP-1 RA) will have stepped up a notch following the announcement by GlaxoSmithKline (GSK) of positive data from the Phase III Harmony 8 study and from the event driven meta-analysis for assessment of cardiovascular safety conducted across the albiglutide clinical programme. Armed with the data, GSK plans to start global regulatory submissions for Syncria (albiglutide) its type 2 diabetes treatment in early 2013.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.